Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

Annals of internal medicine·2026
Same author

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

BJU international·2026
Same author

The clinical utility of prostate MRI before biopsy.

Nature reviews. Urology·2026
Same author

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).

The Journal of urology·2026

Related Experiment Video

Updated: Jun 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

CYP17 polymorphisms and prostate cancer outcomes.

Jonathan L Wright1, Erika M Kwon, Daniel W Lin

  • 1Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA. jlwright@u.washington.edu

The Prostate
|May 27, 2010
PubMed
Summary

Genetic variations in the CYP17 gene may impact prostate cancer (PCa) survival. Specifically, the rs10883783 variant A allele was linked to reduced prostate cancer mortality in Caucasian men.

Related Experiment Videos

Last Updated: Jun 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Cytochrome P450 17alpha-hydroxylases-C-(17,20)-lyase (CYP17) is crucial for androgen biosynthesis.
  • CYP17 is a therapeutic target for advanced prostate cancer (PCa).
  • Previous studies on CYP17 gene variants and PCa outcomes show conflicting results.

Purpose of the Study:

  • To investigate the association between CYP17 gene Single Nucleotide Polymorphisms (SNPs) and PCa survival.
  • To analyze the relationship between CYP17 genetic variations and PCa-specific mortality (PCSM) and recurrence/progression.

Main Methods:

  • Analysis of CYP17 SNPs in a cohort of Caucasian men (aged 40-64) diagnosed with PCa between 1993-1996.
  • Utilized Cox proportional hazards regression to assess hazard ratios for PCa outcomes.
  • PCSM data obtained from SEER cancer registry; recurrence/progression data from patient records.

Main Results:

  • Genotypes were analyzed for 598 PCa cases with a median follow-up of 13.2 years.
  • No significant association found between CYP17 SNPs and PCa disease progression.
  • The variant A allele in rs10883783 was associated with a 56% reduction in PCSM (HR 0.44, 95% CI 0.21-0.98).

Conclusions:

  • Genetic variations within the CYP17 gene are associated with PCa survival in Caucasian men.
  • The rs10883783 SNP may be a predictive marker for PCa-specific mortality.